Attapon Cheepsattayakorn^1,2*, Ruangrong Cheepsattayakorn³ and Porntep Siriwanarangsun¹

¹Faculty of Medicine, Western University, Pathumtani Province, Thailand
²10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
³Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: August 09, 2021;; Published: 00-00

Citation: Attapon Cheepsattayakorn., et al. “Third Doses (Booster) of COVID-19 Vaccination". Acta Scientific Microbiology 4.10 (2021): 27-28.

  Flaxman., et al. a groups of investigators from the University of Oxford, United Kingdom demonstrated the results studied in COVID-19-vaccinated participants in a preprint published on June 28, 2021 that for those who had 8 to 12 week (median age 39), 15 to 25 week (median age 36), and 44 to 45 week (median age 32) intervals between the first and second COVID-19-vaccine doses, the median level of IgG antibody at the day 28 after the second dose were 923, 1,860, and 3,738 tIgG EU, respectively [1]. These results indicated the longer dose intervals the higher IgG-antibody levels [1]. They identified the median 278 and 1,240 tIgG EU in the groups who had a 8 to 12 week and a 15 to 25 week intervals, respectively after 6 months of the second dose, whereas the data for the 44 to 45 week-interval group are not yet available [1]. After the second dose, the IgG binding titers to the four SARS-CoV-2 (COVID-19) variants (alpha, beta, delta, and D6₁₄G) tested were significant higher than before the second dose [1]. Among 75 first-two-dose-received participants with an interval of 8 to 16 weeks, the IgG antibody levels were 1,792 and 3,746 tIgG EU at the day 28 after the second dose and after the third (boosted) dose, respectively [1].

Bibliography

1. Flaxman A., et al. “Tolerability and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 (AZD1222)”. SSRN (Preprint) (2021).
2. Mahase E. “COVID-19: Booster vaccine to be rolled out in authum as a UK secures 60m more Pfizer doses”. BMJ 373 (2021): n1116.
3. Mahase E. “COVID-19: third vaccine dose boosts immune response but may not be needed, say researchers”. BMJ 373 (2021): n1659.
4. Fuentes V and Malinowski M. “Bloomberg. Prognosis: Chile rolls out COVID-19 booster push that mixes vaccines”. Updated on August 6 (2021).
5. News. Posted on July 30, 2021. COVID-19 boosters for wealthy nations spark outrage (2021).

Copyright: © 2021 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.